Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Glaukos is an ophthalmic pharmaceutical and medical device company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases. Its core products include Micro-Invasive Glaucoma Surgery (MIGS) devices, sustained-release pharmaceuticals, and bio-activated therapies. Serving global markets, the company focuses on improving clinical outcomes through proprietary technologies, extensive R&D, and regulatory expertise in ophthalmology. Its business model emphasizes product development, commercialization, and strategic licensing.
This description was generated via AI from an annual report. Updated about 1 year ago.